Evidence map›Paper›PMID 39696327›Full record

ArticleJournal of nanobiotechnology2024

Metabolizable alloy clusters assemble nanoinhibitor for enhanced radiotherapy of tumor by hypoxia alleviation and intracellular PD-L1 restraint.

Guanwen Ding, Shengnan Liu, Xiangshan Yang, Hongying Lv, Mengchao Jia, Juan Li, Rui Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Emerging Nanoplatforms are Effective Against Tumor Hypoxia.International journal of nanomedicine · 2026
    Review
  3. Multifunctional CuFrontiers in chemistry · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guanwen Ding *NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Chang Chun, 130021, China.
Shengnan Liu *China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.
Xiangshan YangNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Chang Chun, 130021, China.
Hongying LvChinese Academy of Medical Sciences Institute of Radiation Medicine, Tianjin, 300192, China.
Mengchao JiaNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Chang Chun, 130021, China.
Juan LiNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Chang Chun, 130021, China. li_juan@jlu.edu.cn.
Rui ZhangNHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Chang Chun, 130021, China. zhangrui625827@jlu.edu.cn.

Funding

Jilin Provincial Natural Science Foundation 20220101193JCJilin University Overseas Doctoral Class A Talent Start-up Project 451210330022
6 · The paper itself

Abstract

backgroundCancer radiotherapy (RT) still has limited clinical success because of the obstacles including radioresistance of hypoxic tumors, high-dose X-ray-induced damage to adjacent healthy tissue, and DNA-damage repair by intracellular PD-L1 in tumor.

resultsTherefore, to overcome these obstacles multifunctional core-shell BMS@Pt

conclusionIn conclusion, the therapeutic outcome supports the high-efficiency of radiotherapy based on BMS@Pt

Indexed as

B7-H1 AntigenAlloysAnimalsApoptosisCell Line, TumorDNA DamageFemaleHumansMetal NanoparticlesMiceMice, Inbred BALB CNanoparticlesNeoplasmsReactive Oxygen SpeciesTumor HypoxiaAlloysB7-H1 AntigenReactive Oxygen SpeciesAlloy clustersAntitumorIntracellular PD-L1RadiotherapyTumor hypoxia

Identifiers

PMID39696327
PMCPMC11657501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.